---
title: "Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention: Safety questions"
description: "Safety questions on Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects and Warnings. Questions: Shingrix side effects: which are most common in adults 50 and older? How common are Shingrix side effects vs placebo by age in adults 50 and older? Are Shingrix side effects worse after the second dose in adults 50 and older? What other Shingrix side effects occurred within 30 days in adults 50 and older? 6 further questions follow. 10 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention: Safety questions

Manufacturer: GlaxoSmithKline Biologicals; GlaxoSmithKline  
Prescribing information: [Shingrix](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF)

Safety questions that apply to every indication of Shingrix are on [Shingrix (Zoster Vaccine Recombinant, Adjuvanted), all indications: Safety](https://www.evicenter.com/medical-information/shingrix/safety).

## Side effects

<a id="shingrix-side-effects"></a>

### Shingrix side effects: which are most common in adults 50 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “Across both studies, the percentages of subjects aged 50 years and 
> older reporting each solicited local and general adverse reaction following administration of SHINGRIX (both 
> doses combined) were pain (78%), redness (38%), and swelling (26%); and myalgia (45%), fatigue (45%), 
> headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%).”

Source: [SHINGRIX: Prescribing information, page 5, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=5)

<a id="shingrix-side-effects-by-age"></a>

### How common are Shingrix side effects vs placebo by age in adults 50 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “Solicited local and general adverse reactions within 7 days of vaccination (data from ZOE-50 & pooled analysis from ZOE-50 & ZOE-70)
> Age	50-59 years old	60-69 years old	≥70 years old
>  	SHINGRIX %	Placebo %	SHINGRIX %	Placebo %	SHINGRIX %	Placebo %
> Local adverse reactions	n=1315	n=1312	n=1311	n=1305	n=2258	n=2263
> Pain	88	14	83	11	69	9
> Pain, Grade 3*	10	1	7	1	4	0.2
> Redness	39	1	38	2	38	1
> Redness, >100 mm	3	0	3	0	3	0
> Swelling	31	1	27	1	23	1
> Swelling, >100 mm	1	0	1	0	1	0
> General
> adverse reactions	n=1315	n=1312	n=1309	n=1305	n=2252	n=2264
> Myalgia	57	15	49	11	35	10
> Myalgia, Grade 3<sup>†</sup>	9	1	5	1	3	0.4
> Fatigue	57	20	46	17	37	14
> Fatigue, Grade 3<sup>†</sup>	9	2	5	1	4	1
> Headache	51	22	40	16	29	12
> Headache, Grade 3<sup>†</sup>	6	2	4	0.2	2	0.4
> Shivering	36	7	30	6	20	5
> Shivering, Grade 3<sup>†</sup>	7	0.2	5	0.3	2	0.3
> Fever<sup>‡</sup>	28	3	24	3	14	3
> Fever, Grade 3<sup>§</sup>	0.4	0.2	1	0.2	0.1	0.1
> GI<sup>‖</sup>	24	11	17	9	14	8
> GI, Grade 3<sup>†</sup>	2	1	1	1	1	0.4
>
> In ZOE-50 and ZOE-70, data on solicited local and general adverse reactions were collected using standardized diary cards for 7 days following each vaccine dose or placebo (ie, day of vaccination and the next 6 days) in a subset of subjects (n=4886 receiving SHINGRIX, n=4881 receiving placebo with at least 1 documented dose). Data for subjects 50-59 years and 60-69 years are from ZOE-50 and data for subjects 70 years and older are based on pooled data from ZOE-50 and ZOE-70.
>
> *
>
> Grade 3 pain defined as significant pain at rest; prevents normal everyday activities.
>
> †
>
> Grade 3 myalgia, fatigue, headache, shivering, and GI: defined as preventing normal activity.
>
> ‡
>
> Fever defined as ≥37.5°C/99.5°F for oral, axillary, or tympanic route, or ≥38°C/100.4°F for rectal route.
>
> §
>
> Grade 3 fever defined as >39.0°C/102.2°F.
>
> ‖
>
> Included nausea, vomiting, diarrhea, and/or abdominal pain.
>
> n=number of subjects with at least 1 documented dose of either SHINGRIX or placebo included in the total vaccinated cohort for safety.”

Source: [SHINGRIX: Safety Profile & Adverse Reactions, captured 2026-11-13](https://shingrixhcp.com/efficacy-safety/adverse-reactions/#:~:text=Solicited%20local%20and%20general%20adverse,total%20vaccinated%20cohort%20for%20safety.)

> “The incidence of solicited local and general reactions was lower in subjects aged 70 years and older compared 
> with those aged 50 through 69 years.”

Source: [SHINGRIX: Prescribing information, page 6, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=6)

<a id="shingrix-second-dose-side-effects"></a>

### Are Shingrix side effects worse after the second dose in adults 50 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “There were no differences in the proportions of subjects reporting any or Grade 3 solicited local reactions 
> between Dose 1 and Dose 2. Headache and shivering were reported more frequently by subjects after Dose 2 
> (28% and 21%, respectively) compared with Dose 1 (24% and 14%, respectively). Grade 3 solicited general 
> adverse reactions (headache, shivering, myalgia, and fatigue) were reported more frequently by subjects after 
> Dose 2 (2.3%, 3%, 4%, and 4%, respectively) compared with Dose 1 (1.4%, 1.4%, 2.3%, and 2.4%, 
> respectively).”

Source: [SHINGRIX: Prescribing information, page 7, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=7)

<a id="shingrix-other-side-effects"></a>

### What other Shingrix side effects occurred within 30 days in adults 50 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “Unsolicited Adverse Events: Unsolicited adverse events that occurred within 30 days following each 
> vaccination (Day 0 to 29) were recorded on a diary card by all subjects. In the 2 studies, unsolicited adverse 
> events occurring within 30 days of vaccination were reported in 51% and 32% of subjects who received 
> SHINGRIX (n = 14,645) or placebo (n = 14,660), respectively (Total Vaccinated Cohort). Unsolicited adverse 
> events that occurred in ≥1% of recipients of SHINGRIX and at a rate at least 1.5-fold higher than placebo 
> included chills (4% versus 0.2%), injection site pruritus (2.2% versus 0.2%), malaise (1.7% versus 0.3%), 
> arthralgia (1.7% versus 1.2%), nausea (1.4% versus 0.5%), and dizziness (1.2% versus 0.8%).”

Source: [SHINGRIX: Prescribing information, page 7, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=7)

> “Gout (including gouty arthritis) was reported by 0.18% (n = 27) versus 0.05% (n = 8) of subjects who received 
> SHINGRIX or placebo, respectively, within 30 days of vaccination; available information is insufficient to 
> determine a causal relationship with SHINGRIX.”

Source: [SHINGRIX: Prescribing information, page 7, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=7)

> “Optic ischemic neuropathy was reported in 3 subjects (0.02%) who received SHINGRIX (all within 50 days 
> after vaccination) and 0 subjects who received placebo; available information is insufficient to determine a 
> causal relationship with SHINGRIX.”

Source: [SHINGRIX: Prescribing information, page 7, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=7)

<a id="shingrix-serious-adverse-events"></a>

### Shingrix serious adverse events vs placebo: how common in adults 50 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “Serious Adverse Events (SAEs): In the 2 studies, SAEs were reported at similar rates in subjects who received 
> SHINGRIX (2.3%) or placebo (2.2%) from the first administered dose up to 30 days post-last vaccination. 
> SAEs were reported for 10.1% of subjects who received SHINGRIX and for 10.4% of subjects who received 
> placebo from the first administered dose up to 1 year post-last vaccination. One subject (<0.01%) reported 
> lymphadenitis and 1 subject (<0.01%) reported fever greater than 39°C; there was a basis for a causal 
> relationship with SHINGRIX.”

Source: [SHINGRIX: Prescribing information, page 7, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=7)

> “Deaths: From the first administered dose up to 30 days post-last vaccination, deaths were reported for 0.04% of 
> subjects who received SHINGRIX and 0.05% of subjects who received placebo in the 2 studies. From the first 
> administered dose up to 1 year post-last vaccination, deaths were reported for 0.8% of subjects who received 
> SHINGRIX and for 0.9% of subjects who received placebo. Causes of death among subjects were consistent 
> with those generally reported in adult and elderly populations.”

Source: [SHINGRIX: Prescribing information, page 7, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=7)

<a id="shingrix-side-effects-immunocompromised"></a>

### What are Shingrix side effects in immunocompromised adults 18 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

> “Inform patients that they may experience adverse reactions after receiving SHINGRIX. In clinical trials in immunocompromised patients aged 18 years and older, the following solicited adverse reactions were reported more frequently in the SHINGRIX groups compared to placebo groups*:
> Local adverse reactions: pain, redness, and swelling
> General adverse reactions: fatigue, myalgia, headache, gastrointestinal symptoms, shivering, and fever<sup>2</sup>”

Source: [SHINGRIX: Patient Counseling, captured 2026-11-14](https://shingrixhcp.com/home-ic/in-your-practice/patient-counseling/#:~:text=Inform%20patients%20that%20they%20may,headache%2C%20gastrointestinal%20symptoms%2C%20shivering%2C%20and)

> “Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)”

Source: [SHINGRIX: Safety Profile, captured 2026-11-14](https://shingrixhcp.com/home-ic/efficacy-safety/adverse-reactions/#:~:text=Solicited%20local%20adverse%20reactions%20reported%20in%20autologous,and%20swelling%20%2821%25%20and%2018%25%29)

> “Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)”

Source: [SHINGRIX: Safety Profile, captured 2026-11-14](https://shingrixhcp.com/home-ic/efficacy-safety/adverse-reactions/#:~:text=Solicited%20general%20adverse%20reactions%20reported%20in%20autologous,and%20fever%20%2828%25%20and%2018%25%29)

> “In general, the reported frequencies of solicited local and general adverse reactions in the other studies in immunocompromised populations were similar to that of the autologous hematopoietic stem cell transplant study.”

Source: [SHINGRIX: Safety Profile, captured 2026-11-14](https://shingrixhcp.com/home-ic/efficacy-safety/adverse-reactions/#:~:text=In%20general%2C%20the%20reported%20frequencies,hematopoietic%20stem%20cell%20transplant%20study.)

Note: The percentages are from the auHSCT study (NCT01610414), the largest of the 6 studies in immunocompromised adults. The first passage is from the Patient Counseling page and the others from the Safety Profile page of the immunocompromised section of the Shingrix HCP site.

<a id="shingrix-serious-adverse-events-immunocompromised"></a>

### Shingrix serious adverse events: how common in immunocompromised adults 18 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

> “Unsolicited Adverse Events: Across all 6 studies enrolling immunocompromised subjects, unsolicited adverse 
> events, including both serious and non-serious events, occurring within 30 days following each vaccination”

Source: [SHINGRIX: Prescribing information, page 11, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=11)

> “were reported in 46% and 44% of subjects who received SHINGRIX or placebo. Adverse events of arthralgia, 
> infective pneumonia, and influenza-like illness occurred in ≥1% of recipients of SHINGRIX and at a rate at 
> least 1.5-fold higher than placebo (1.5% versus 1.0%, 1.5% versus 0.9%, and 1.3% versus 0.6%, respectively). 
> Serious Adverse Events: Across all 6 studies enrolling immunocompromised subjects, SAEs were reported at 
> similar rates in subjects who received SHINGRIX (7%) or placebo (8%) from the first administered dose up to 
> 30 days post-last vaccination. SAEs were reported for 26% of subjects who received SHINGRIX and for 27% 
> of subjects who received placebo from the first administered dose up to 1 year post-last vaccination. SAEs of 
> infective pneumonia were reported for 21 subjects (1.3%) who received SHINGRIX and for 11 subjects (0.7%) 
> who received placebo up to 30 days post-last vaccination. Available information is insufficient to determine a 
> causal relationship to vaccination. 
> Deaths: Across all 6 studies enrolling immunocompromised subjects, from the first administered dose up to 
> 30 days post-last vaccination, deaths were reported for 2 subjects (0.1%) who received SHINGRIX and 7 
> subjects (0.5%) who received placebo. From the first administered dose up to 1 year post-last vaccination, 
> deaths were reported for 6% of subjects who received SHINGRIX and for 6% of subjects who received placebo. 
> Causes of death among subjects were consistent with those expected in the populations evaluated.”

Source: [SHINGRIX: Prescribing information, page 12, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=12)

## Safety

<a id="shingrix-immune-mediated-diseases"></a>

### Does Shingrix increase immune-mediated diseases vs placebo in adults 50 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “Potential Immune-Mediated Diseases: In the 2 studies, new onset potential immune-mediated diseases (pIMDs) 
> or exacerbation of existing pIMDs were reported for 0.6% of subjects who received SHINGRIX and 0.7% of 
> subjects who received placebo from the first administered dose up to 1 year post-last vaccination. The most 
> frequently reported pIMDs occurred with comparable frequencies in the group receiving SHINGRIX and the 
> placebo group.”

Source: [SHINGRIX: Prescribing information, page 7, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=7)

<a id="shingrix-relapse-rejection-immunocompromised"></a>

### Did Shingrix affect relapse, graft rejection, or HIV vs placebo in immunocompromised adults?

Applies to: Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

> “Other Medically Relevant Events: In the auHSCT study (NCT01610414), relapse or progression was reported 
> by 315 of 922 subjects (34%) who received at least 1 dose of SHINGRIX and 331 of 924 subjects (36%) who 
> received placebo from the first vaccination to study end. 
> In the auHSCT study (NCT00920218), relapse or progression was reported by 17 of 59 subjects (29%) who 
> received at least 1 dose of SHINGRIX and 8 of 30 subjects (27%) who received placebo from the first 
> vaccination to study end. 
> In the hematologic malignancy study, relapse or progression was reported by 45 of 283 subjects (16%) who 
> received at least 1 dose of SHINGRIX and 58 of 279 subjects (21%) who received placebo from the first 
> vaccination to study end. 
> In the renal transplant study, biopsy-confirmed allograft rejection was reported by 4 of 132 (3%) of subjects 
> who received SHINGRIX and by 7 of 132 (5%) of subjects who received placebo from the first vaccination to 
> study end (approximately 13 months later). Creatinine as a measure of graft function and changes in 
> alloimmunity postvaccination were not systematically evaluated. 
> In the HIV study, at least 1 event of worsening HIV condition was reported by 9 of 74 (12%) of subjects who 
> received SHINGRIX and by 5 of 49 (10%) of subjects who received placebo from the first vaccination to study 
> end.”

Source: [SHINGRIX: Prescribing information, page 12, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=12)

Note: The Safety Profile page of the immunocompromised section of the Shingrix HCP site gives the Shingrix denominator of the NCT01610414 study as 992 in its table; the Prescribing Information gives 315 of 922.

## Warnings

<a id="shingrix-guillain-barre"></a>

### Does Shingrix increase the risk of Guillain-Barré syndrome (GBS)?

Applies to: Medicare beneficiaries aged 65 years or older (postmarketing observational studies of Guillain-Barre syndrome)

> “In postmarketing observational studies, an increased risk of GBS has been observed during the 42 days 
> following vaccination with SHINGRIX [see Adverse Reactions (6.2)].”

Source: [SHINGRIX: Prescribing information, page 4, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=4)

> “The association between vaccination with SHINGRIX and GBS was evaluated among Medicare beneficiaries 
> aged 65 years or older in two studies. The results of each of these studies suggest a causal association of GBS 
> with SHINGRIX.”

Source: [SHINGRIX: Prescribing information, page 13, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=13)

> “In one study, using Medicare claims data, from October 2017 through February 2020, vaccinations with 
> SHINGRIX among beneficiaries were identified through National Drug Codes, and potential cases of 
> hospitalized GBS among recipients of SHINGRIX were identified through International Classification of 
> Diseases codes. 
> The risk of GBS following vaccination with SHINGRIX was assessed in self-controlled case series analyses 
> using a risk window of 1 to 42 days postvaccination and a control window of 43 to 183 days postvaccination. 
> Medical record review of GBS cases was conducted to estimate the Positive Predictive Value (PPV) of the 
> claims algorithm. PPV-adjusted risk estimates were calculated by imputing GBS status for all claims-identified 
> cases. These analyses included GBS cases in which other vaccinations were administered the same day or 
> within 42 days of SHINGRIX. The primary analysis, which did not distinguish between doses, found an 
> increased risk of GBS during the 42 days following vaccination with SHINGRIX, with an estimated 3 excess 
> cases (95% confidence interval [CI]: 0.6, 5.6) of GBS per million doses administered to adults aged 65 years or 
> older. In secondary analyses, an increased risk of GBS was observed during the 42 days following the first dose 
> of SHINGRIX, with an estimated 6 excess cases (95% CI: 3.4, 9.6) of GBS per million doses administered to 
> adults aged 65 years or older, and no increased risk of GBS was observed following the second dose of 
> SHINGRIX. 
> A separate similarly-designed study also evaluated the association between vaccination with SHINGRIX and 
> GBS among Medicare beneficiaries aged 65 years or older. Using Medicare claims data, from January 2018 
> through December 2020, vaccinations with SHINGRIX among beneficiaries were identified through National 
> Drug Codes and Current Procedural Terminology codes. Potential cases of hospitalized GBS among recipients 
> of SHINGRIX were identified through International Classification of Diseases codes.”

Source: [SHINGRIX: Prescribing information, page 13, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=13)

> “The primary 
> and secondary analyses included GBS cases in which other vaccinations were administered the same day or 
> within 42 days of SHINGRIX. The primary analysis, which did not distinguish between doses, found an 
> increased risk of GBS during the 42 days following vaccination with SHINGRIX, with an estimated 7 excess 
> cases (95% CI 4.4, 8.0) of GBS per million doses administered to adults aged 65 years or older. This analysis of 
> GBS diagnoses in claims data was supported by a post hoc analysis excluding GBS cases in individuals who 
> received pneumococcal, influenza, and/or tetanus, diphtheria and pertussis (Tdap) vaccines on the same day or 
> in the 42 days prior to SHINGRIX vaccination. In secondary analyses, an increased risk of GBS was observed 
> during the 42 days following the first dose of SHINGRIX, with an estimated 12 excess cases (95% CI 8.9, 13.4) 
> of GBS per million doses administered to adults aged 65 years or older, and no increased risk of GBS was 
> observed following the second dose of SHINGRIX.”

Source: [SHINGRIX: Prescribing information, page 14, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=14)

Note: The Prescribing Information lists this Guillain-Barré syndrome warning (section 5.2) under Recent Major Changes, dated 2/2026.

## Related pages
- [Medical information: Shingrix (Zoster Vaccine Recombinant, Adjuvanted): Herpes zoster prevention](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention)
- [Indication](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/guidelines)
